PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE

100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:


Scientific evidence for clinical utility.

By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrintยฎ and BluePrintยฎ test suite.

Evidence

Molecular profiles of genomically High Risk ER+ HER2- breast cancer tumors classified as functionally Basal or Luminal B by the BluePrint

PUBLICATION: ASCO 2021 ย  Authors Joyce Oโ€™Shaughnessy1, Virginia G. Kaklamani2, Yuan Yuan3, Julie Barone4, Sami Diab5, Jennifer A. Crozier6, Pat W. Whitworth7, Karen L. Tedesco8, Robert Maganini9, Rakhshanda Layeequr Rahman10, Carlos A. Encarnacion11, Josien Haan12, Amy M. Truitt12, Andrea Menicucci12, William Audeh12, FLEX Investigatorsโ€™ Group13 Background The 80-gene signature Read More

Whole transcriptome analysis comparing HR+ HER2- breast cancer tumors from patients โ‰ค 50 years and > 50 years

PUBLICATION: ASCO 2021 ย  Authors Cathy Graham1, Douglas K. Marks2, Nina Dโ€™Abreo2, Sami Diab3, Vijayakrishna K. Gadi4, Midas M. Kuilman5, Andrea Menicucci6, Amy M. Truitt6, Shiyu Wang6, Patricia Dauer6, William Audeh6, FLEX Investigatorsโ€™ Group8 Background Recent prospective clinical trials have demonstrated a differential chemotherapy effect based on age (โ‰ค Read More

Gene expression associated with lymphovascular invasion and genomic risk in early-stage breast cancer

PUBLICATION: ASCO 2021 Authors Nina Dโ€™Abreo1,2, Abhinav Rohatgi1,2, Douglas Kanter Marks1,2, Heather M. Kling3, Josien Haan4, William Audeh3, FLEX Investigators Group5 Background Lymphovascular invasion (LVI), the passage of carcinoma cells through lymphatic and blood vessels, is an important early step in metastasis; however, LVI is excluded from most breast Read More

MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles (FLEX): A real-world dataset and investigator-initiated protocols in ESBC

ย  Publication: St. Gallen Authors: Jennifer A. Crozier, Lisa Blumencranz, Miranda Kleijn, Heather Kling, Amy M. Truitt, Darina Proni, Christine Finn, William Audeh, Bastiaan van der Baan, FLEX Investigatorsโ€™ Group Background: The personalized management of early-stage breast cancers is enhanced by the ability of genomic signatures to stratify tumors into Read More